Maintaining Nonsmoking

PHASE3CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Nicotine Dependence
Interventions
DRUG

Varenicline

All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.

BEHAVIORAL

Initial Individual counseling

Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.

BEHAVIORAL

Check-ins with medical staff

Monthly brief (10-15 minutes) meetings with medical staff.

BEHAVIORAL

Extended Individual Counseling - Health Model

Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.

BEHAVIORAL

Extended Individual Counseling - Relapse Prevention Model

Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Pfizer

INDUSTRY

lead

University of California, San Francisco

OTHER